Evidence map›Paper›PMID 42277430›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Survival benefit of ⁶⁸Ga-FAPI PET/CT staging for prognostic assessment in gastric and colorectal cancer compared with CE-CT and ¹⁸F-FDG PET/CT: a single-center retrospective study.

Xiaoxiao Wu, Lingyu Ma, Yan Zhao, Guohong Cai, Jingyi Wang, Ying Guo, Yuanyuan Lu, Yan Pan, Xinyu Du, Yongzhan Nie and 2 more

Erratum issuedAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Xiaoxiao Wu *Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China.
Lingyu Ma *Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China.
Yan Zhao *Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China.
Guohong Cai *Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China.
Jingyi WangDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China.
Ying GuoDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China.
Yuanyuan LuState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China.
Yan PanState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China.
Xinyu DuState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China.
Yongzhan NieState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China. yongznie@fmmu.edu.cn.
Fei KangDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China. fmmukangf@fmmu.edu.cn.ORCID 0000-0003-0267-7819
Jing WangDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China. 13909245902@163.com.

Funding

Key Industry Innovation Chain of Shaanxi 2024SF-ZDCYL-02-06Major Program of Scientific and Technological Innovation: Brain Science and Brain-inspired Research 2022ZD0208000National Natural Science Foundation of China 92259304Xijing hospital Medical Personnel Training Promotion Project 2024XJSM04Xijing hospital Medical Personnel Training Promotion Project 2024XJSY35Xijing hospital Medical Personnel Training Promotion Project XJZT24JC15Xijing hospital Medical Personnel Training Promotion Project XJZT24LZ03
6 · The paper itself

Abstract

purposeThe aim of this retrospective study was to investigate whether gallium-68-labeled fibroblast activation protein inhibitor (⁶⁸Ga-FAPI) positron emission tomography/computed tomography (PET/CT) that provided altered staging and adjusted treatment decisions was more effective for prolonging patient survival compared to that achieved by either contrast-enhanced computed tomography (CE-CT) or fluorine-18-fluorodeoxyglucose (¹⁸F-FDG) PET/CT.

methodsWe analyzed patients diagnosed with untreated gastric or colorectal cancer between March 2021 and March 2023 who were staged using these three imaging diagnostic modes described above. The accuracy of staging, reduction of unnecessary surgery, progression-free survival (PFS), and overall survival (OS) were used as the main comparative indicators. The potential independent risk factors affecting the prognosis of patients with gastric or colorectal cancer were also analyzed.

resultsA total of 270 patients (137 gastric and 133 colorectal cancers) were enrolled, with a median follow-up of 3.02 years (95%CI: 2.7-3.3 years). The baseline characteristics of the patient groups were comparable. For both cancers, patients staged by ⁶⁸Ga-FAPI PET/CT had significantly longer median OS than those staged by either CE-CT or ¹⁸F-FDG PET/CT (colorectal cancer: p = 0.0123; gastric cancer: p = 0.037). ⁶⁸Ga-FAPI PET/CT also improved the accuracy of staging and altered staging in 41%-52% of patients, with a reduction in unnecessary surgeries of 42%-69%. Cox multivariate regression identified CE-CT and ¹⁸F-FDG PET/CT as prognostic risk factors relative to ⁶⁸Ga-FAPI PET/CT.

conclusionIn patients with gastric or colorectal cancer, those who underwent staging with

Indexed as

Colorectal NeoplasmsFluorodeoxyglucose F18Positron Emission Tomography Computed TomographyStomach NeoplasmsAdultAgedAged, 80 and overContrast MediaFemaleFibroblast Activation Protein AlphaGallium RadioisotopesHumansMaleMiddle AgedNeoplasm StagingPrognosis68Ga-FAPIContrast MediaFibroblast Activation Protein AlphaFluorodeoxyglucose F18Gallium RadioisotopesQuinolines68Ga-FAPI PET/CTColorectal cancerGastric cancerOverall survivalPrognosis

Identifiers

PMID42277430

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.